News | Interventional Radiology | August 20, 2019

Boston Scientific Closes Acquisition of BTG plc

Transaction brings BTG’s Interventional Medicine portfolio under Boston Scientific

Boston Scientific Closes Acquisition of BTG plc

August 20, 2019 — Boston Scientific Corp. announced the completion of its acquisition of BTG plc. pursuant to the previously announced scheme of arrangement. BTG develops and commercializes products used in minimally invasive procedures targeting cancer and vascular diseases, as well as specialty pharmaceuticals.

BTG has three key businesses, the largest of which is its Interventional Medicine portfolio. This encompasses interventional oncology therapeutic technologies for patients with liver and kidney cancers, as well as a vascular portfolio for treatment of deep vein thrombosis, pulmonary embolism, deep venous obstruction and superficial venous disease.

In addition to the Interventional Medicine product lines, the BTG portfolio also includes: 

  • A specialty pharmaceutical business comprised of acute care antidotes to treat overexposure to certain medications and toxins; and 
  • A licensing business that receives royalties related to BTG intellectual property and product license agreements.

Upon the effectiveness of the scheme of arrangement, BTG became a wholly-owned subsidiary of Boston Scientific, and BTG shares no longer trade on the London Stock Exchange. Under the terms of the previously announced transaction, holders of BTG common shares will receive 840 pence in cash per share.

Boston Scientific expects to complete the previously announced sale of its global embolic microspheres portfolio – comprised of Embozene, Embozene Tandem and Oncozene brands – to Varian Medical Systems Inc. in due course. The products in question are used to treat arteriovenous malformations and hypervascular tumors. This transaction was entered into in connection with obtaining the antitrust clearances required to complete the BTG transaction.

Read the article “Varian Purchasing Embolic Bead Assets from Boston Scientific”

In addition, the company is initiating a process to explore the divestiture of the royalty stream associated with BTG's Zytiga licensing arrangements and anticipates closing this divestiture by the end of 2019.

The transaction is expected to be immaterial to adjusted earnings per share in 2019 as a result of the BTG transaction closing later than originally anticipated, the divestiture of the Boston Scientific embolic microspheres portfolio, and the treatment of the licensing business as an asset for accounting purposes and its intended divestiture. The transaction is expected to be four to five cents accretive in 2020 on an adjusted basis, and increasingly accretive thereafter. On a GAAP basis, the transaction is expected to be less accretive, or more dilutive as the case may be, due to amortization expense and acquisition-related net charges.

The acquisition of BTG is the second interventional oncology-related acquisition by Boston Scientific in the last year. In October 2018, the company finalized the acquisition of Augmenix Inc., developer of the SpaceOAR hydrogel system to limit common and debilitating side effects of prostate cancer radiotherapy. 

Read the article “Boston Scientific Closes Acquisition of Augmenix Inc.”

For more information: www.bostonscientific.com

Related Content

Harel Gadot

Harel Gadot, Founder, Executive Chairman and President at XACT Robotics says their system’s small footprint and high mobility design will enable care providers to treat a broad range of patient care needs.

News | Interventional Radiology | November 01, 2019
November 1, 2019 — XACT Robotics Ltd. announced that its firs
The Alphenix Aero Package from Canon Medical Systems USA, Inc. enables OBLs and ASCs to attain premium technology at a flexible price point by tailoring Canon Medical’s Alphenix systems to fit their facilities’ needs.

The Alphenix Aero Package from Canon Medical Systems USA, Inc. enables OBLs and ASCs to attain premium technology at a flexible price point by tailoring Canon Medical’s Alphenix systems to fit their facilities’ needs.

Technology | Interventional Radiology | October 28, 2019
October 28, 2019 — Office based labs (OBLs) and ambulatory surgery centers (ASCs) require a fresh perspective from im
Exact Imaging Receives FDA 510(k) Clearance for Sterile Transperineal Needle Guide
Technology | Ultrasound Imaging | October 24, 2019
Exact Imaging received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Sterile Transperineal Needle...
Canon Medical Launches Alphenix Encore Plus Program
News | Angiography | October 09, 2019
In the complex and fast-paced world of healthcare, customers face the challenge of staying up-to-date with the most...
The Artis icono biplane angiography system is designed for use in neurointerventions and interventional radiology

The Artis icono biplane angiography system is designed for use in neurointerventions and interventional radiology. Image courtesy of Siemens Healthineers.

Technology | Angiography | September 17, 2019
The U.S. Food and Drug Administration (FDA) has cleared the Artis icono, a high-precision family of angiography systems...
Adept Medical Launches Antegrade IR Platform
Technology | Interventional Radiology | September 03, 2019
New Zealand-based Adept Medical announced the launch of the Antegrade IR Platform. Clinically driven, it is placed to...
Study Finds Growth in Paracentesis and Thoracentesis Procedures

Image source: Blausen.com staff (2014). "Medical gallery of Blausen Medical 2014". WikiJournal of Medicine 1 (2). DOI:10.15347/wjm/2014.010. ISSN 2002-4436. [CC BY 3.0 (https://creativecommons.org/licenses/by/3.0)]

News | Interventional Radiology | August 27, 2019 | Jeff Zagoudis, Associate Editor
A new Harvey L. Neiman Health Policy Institute study assesses temporal and patient-level differences in paracentesis...
Jackson Memorial Hospital Holds Ribbon-cutting for New Cardiac Catheterization Labs
News | Angiography | August 21, 2019
Jackson Memorial Hospital in Miami celebrated the opening of two newly renovated cardiac catheterization suites during...
Profound Medical Receives U.S. FDA 510(k) Clearance for Tulsa-Pro
Technology | Interventional Radiology | August 16, 2019
Profound Medical Corp. announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to...